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 ABSTRACT 
Laminitis remains a poorly understood form of lameness in the horse despite being 
heavily researched. Endocrinopathic laminitis is an insidious form of laminitis that often results 
from insulin resistance (an indicator of Equine Metabolic Syndrome or EMS) or equine pituitary 
pars intermedia dysfunction (PPID). Both conditions occur in older horses with PPID having a 
later age of onset than EMS and horses are often characterized as having a “cresty” neck. EMS 
horses have persistent hyperinsulinemia while horses affected by PPID have elevated ACTH 
levels. Though no specific genetic predispositions have been identified for EMS or PPID, ponies 
are frequently observed to have both conditions. The objective of this study was to conduct a 
genome-wide association to identify candidate genes that may predispose individuals to EMS, 
PPID or both. A total of 65 horses, at least ten years old and of full or majority Arabian descent 
were divided into four categories based on previous endocrinology testing. Horses with ACTH 
levels greater than 70 pg/mL and insulin levels less than 40 uIU/mL were designated “PPID” 
while horses with insulin levels > 70 uIU/mL and ACTH levels less than 40 pg/mL were 
designated “EMS”. Horses with ACTH and insulin levels < 40 pg/mL or uIU/mL, respectively, 
were considered “Normal” and those with both levels > 70 were grouped into the fourth category 
termed “Both”. The Illumina Infinium® II Assay (Illumina Inc, San Diego, CA, USA) was 
performed on the EquineSNP 50 Genotyping BeadChip (Illumina Inc, San Diego, CA, USA) 
using DNA extracted from tail hair or blood samples. Data was analyzed using the PLINK v1.07 
Whole genome association analysis toolset and JMP 8.0 (SAS Insitute Inc, Cary, NC, USA). 
Basic association (chi-square) tests were used to compare various groupings of disease cases and 
controls for a total of 15 qualitative associations. Quantitative associations were also performed 
for highest recorded ACTH (excluding August-October measurements) and insulin levels. An 
additional association was performed comparing horses with at least one episode of laminitis 
versus those with no recorded history of laminitis, regardless of disease category. SNPs with a 
missing genotype rate greater than 10% were excluded from analysis. SNPs in linkage 
disequilibrium (r
2 
> 0.99) were pruned to a single SNP per haplotype block in all graphs. Any 
  
SNPs exceeding the Bonferroni α threshold were mapped on the UCSC Genome Browser using 
the September 2007 assembly (EquCab2.0) of the horse genome. Candidate genes were 
identified within ~50 kb of each significant SNP. A total of 68 SNPs representing 59 different 
loci exceeded the significance threshold after correction for multiple testing. The most 
significant SNP, BIEC2-215377 (ECA 13) with a P-value of 4.34 e-7, was identified in the 
quantitative association with the highest ACTH level recorded for each individual. This SNP 
yielded one candidate gene, XPO6. Other SNPs that did not exceed the significance threshold but 
did vary from their expected P-value in a quantile-quantile plot include BIEC2-770354 (ECA3) 
and its neighboring SNP in linkage disequilibrium, BIEC2-770355 which yielded two candidate 
genes, FTO and ATP5H. This study resulted in the discovery of several good candidate genes 
that are worthy of fine mapping. However, epistatic effects may hamper the ability to identify all 
genetic predispositions. Improvements in diagnostic testing may allow for more specific 
classification of disease categories and refinement of the current data set. The present study is 
also limited by the relatively limited coverage of the Equine SNP50 chip. Expanded platforms 
with better coverage may allow for the discovery of more candidate genes. 
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CHAPTER 1 
Review of Literature 
Introduction 
 Laminitis remains a poorly understood form of lameness in the horse despite 
being heavily researched. While many studies have focused on the pathophysiology of 
acute onset laminitis due to experimental models like carbohydrate overload 
[1]
 and 
black walnut extract 
[2]
, attention is now being given to an insidious form of laminitis 
referred to as endocrinopathic laminitis 
[3]
. Endocrinopathic laminitis is often a result 
of insulin resistance (associated with equine metabolic syndrome) or equine pituitary 
pars intermedia dysfunction (aka equine Cushing’s Disease).  Both equine metabolic 
syndrome and pituitary pars intermedia dysfunction show similar phenotypes and can 
be difficult to distinguish without diagnostic testing. There are currently no cures for 
either condition, though some management and drug therapies are available.  
Equine Metabolic Syndrome 
 The term equine metabolic syndrome (EMS) was first coined in 2002 by 
Johnson to describe horses that show signs of chronic/previous laminitis in the 
absence of acute triggers such as carbohydrate overload or colic 
[4]
. These horses are 
often obese and referred to as “easy keepers” because of their ability to maintain body 
weight with decreased caloric intake. The core characteristics of a horse affected by 
EMS are increased adiposity (often regional), insulin resistance (characterized by 
hyperinsulinemia) and a predisposition towards laminitis 
[4]
. Johnson noted the age of 
onset to range from 8-18 years 
[4]
, though cases have occasionally appeared outside of 
this age range. 
 Obesity in horses is not as clearly defined as the body mass index designed for 
humans 
[5]
 because the popular Henneke scale 
[6]
 does not account for regional 
adiposity. While generalized obesity is often linked to insulin resistance in horses 
[7]
, 
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regional adiposity is now gaining recognition as a high risk factor for insulin 
resistance 
[8, 9]
. The regional adiposity often seen in an EMS affected horse manifests 
as a “cresty neck” in which fat accumulates along the nuchal ligament on the dorsal 
side of the neck. Larger mean neck circumference has previously been shown to be 
associated with lowered glucose tolerance 
[8]
.This regional adiposity is comparable to 
the accumulation of fat around the waist in humans, a characteristic that is a risk factor 
for human metabolic syndrome 
[10]
. Since the Henneke scale does not properly address 
this issue, an objective scoring system for quantifying the relative size of the crest of 
the neck has been developed with scores ranging from 0 to 5 
[11]
. Horses with scores 
greater than or equal to 3 are classified as having an excessively cresty neck. Horses in 
this category also tend to have regional fat accumulation in the supraorbital fat pads, 
tail head and the shoulder area 
[4]
. 
 Hyperinsulinemia, an indication of insulin resistance 
[8, 12, 13]
, is a key 
characteristic of EMS 
[4]
. While the plasma insulin concentration in fasted, healthy 
horses is often less than 20 uIU/mL 
[14]
, insulin resistant horses can have levels in 
excess of 70 uIU/mL 
[15]
. Ponies with a history of laminitis were observed to have 
higher levels of insulin when compared to non-laminitic ponies 
[16]
. In addition, 
induction of hyperinsulinemia, while maintaining euglycemia, has been shown to 
induce laminitis in otherwise healthy ponies and horses 
[17, 18]
. Though both of these 
studies used insulin concentrations in excess of the normal physiological range (>1000 
uIU/mL), the onset of laminitis in the presence of an acute increase in insulin indicates 
that laminitis may also be brought on by prolonged or chronic hyperinsulinemia at 
physiological levels 
[17, 18]. It’s possible that hyperinsulinemia alone does not bring 
about a laminitic episode; rather it predisposes insulin resistant horses to developing 
laminitis due to other causes. For example, acute ingestion of a large amount of 
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nonstructural carbohydrates in feed or pasture that leads to disruption of the microbial 
ecology of the intestine.  
 Hyperglycemia is often seen in humans as a result of insulin resistance and β 
cell failure 
[19]
. However, hyperglycemia is rarely observed in horses with insulin 
resistance 
[16, 20]
, though isolated cases have been reported 
[21]
. Place et al. (2010) 
observed significantly higher blood glucose levels in EMS affected horses than in 
controls, but the levels were still within the reference range 
[22]
. It has been proposed 
that resistance to hyperglycemia in horses may be due to more robust β cell function 
than that of humans 
[20]
. It is also possible that horses simply do not have a long 
enough lifespan for β cell failure (and subsequent hyperglycemia) to develop [20].  
 The repeated postprandial hyperinsulinemia that results from consumption of 
diets high in nonstructural carbohydrates may bring about the development of insulin 
resistance in the horse 
[23]
 and, subsequently, hyperinsulinemia. Alternatively, 
hyperinsulinemia may also be due to hepatic insulin resistance where insulin clearance 
from the liver is lower 
[24]
. Insulin normally acts to stimulate glucose uptake in skeletal 
and adipose tissue by the recruitment of the GLUT4 glucose transport protein to the 
cell surface. In ponies, GLUT4 stimulation is lower than that observed in pigs and 
cows which may account for their susceptibility to insulin resistance 
[25]
. Insulin 
resistant horses in general show decreased basal levels of active cell-surface GLUT4, 
though overall GLUT4 content remains the same 
[26]
. Waller et al. used a biotinylated 
bis-mannose photolabeled technique that was able to distinguish active cell-membrane 
GLUT4 
[26]
 while other studies simply used fractionation which only determines 
GLUT4 content. It may be worthwhile to repeat the work done by Duehlmeier et al. to 
see if pony breeds have decreased active GLUT4 when compared to horses. 
Equine Metabolic Syndrome Diagnostic Testing  
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Many different diagnostic tests have been investigated to assess the degree of 
insulin sensitivity and insulin resistance in horses with metabolic syndrome. The 
resting plasma concentration of insulin has been shown to be a useful diagnostic test 
for insulin resistance 
[8]
. Insulin and glucose responses to feeding are higher in the 
morning 
[27]
, so fasting insulin levels are preferred. Insulin concentrations do not 
appear to be influenced seasonally 
[22, 28]
. The cutoff for hyperinsulinemia is variable 
among testing labs and researchers. Values ranging from 32 uIU/mL 
[29]
 to 70 uIU/mL 
[15]
 have been used to identify insulin resistance and EMS. 
Eiler et al. developed the combined glucose insulin tolerance test in response 
to the need of practitioners to have a test that is easily applied to a clinical setting 
[30]
. 
Horses are first fasted and baseline blood samples are drawn. Then, via catheter, 
dextrose followed by insulin infusions are administered and a second blood sample is 
drawn 45 minutes later. The blood samples are measured for both glucose and insulin 
levels and failure to return to baseline glucose levels by 45 minutes or the maintenance 
of elevated insulin levels indicates decreased insulin sensitivity 
[31]
. The advantage of 
this test is that it takes less than one hour to collect all necessary samples and minimal 
endocrinology testing is required. However, this test may not be accurate when 
performed during a laminitic episode 
[31]
 and placement of catheters the night before 
the test is recommended. 
A technique often used to assess insulin sensitivity in a research setting is the 
frequently sampled intravenous glucose tolerance test (FSIGTT) 
[32][13, 21, 26, 33, 34]
. A 
minimal model analysis is used to determine the value of the acute insulin response to 
glucose (AIRg) and insulin sensitivity. Higher AIRg values have been linked with 
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lower insulin sensitivity in horses and ponies 
[35]
. The FSIGTT involves injecting 100 
mg/kg bodyweight dextrose followed by 20 mu/kg bodyweight insulin after 20 
minutes 
[36]
. Twenty-eight blood samples are then drawn at various times up to 180 
minutes after the dextrose injection. Samples are measured for insulin and glucose 
plasma concentrations and the area under the curve for both insulin and glucose are 
calculated. The biggest drawback to this test is the number of samples needed and the 
length of time required to complete the test. However, this test is more specific to 
insulin sensitivity than the basal plasma insulin concentration, which only identifies 
the presence or absence of hyperinsulinemia. Due to its labor intensive nature, this 
diagnostic test is not often used in a clinical setting. 
Equine Metabolic Syndrome Treatments and Therapies 
 Metformin is an oral biguanide used to improve insulin sensitivity and is the 
most widely prescribed drug for the treatment of type II diabetes in humans 
[37]
. The 
efficacy of metformin in the horse is still being assessed. Vick et al. found that 
metformin was not effective long term for obese mares 
[38]
. However, the higher 
dosage administered by Durham et al. showed improvement in insulin sensitivity up to 
220 days but insulin resistance proxies failed to continue to decrease after two weeks 
[20]
. As recurrent episodes of laminitis are linked to decreased insulin sensitivity 
[16]
, 
Durham et al. noted that metformin may be more effective prior to the first bout of 
laminitis 
[20]
. The low bioavailability of metformin in the horse 
[39]
 may account for the 
lack of efficacy seen in previous studies and higher dosages may be needed to fully 
evaluate metformin as a treatment for EMS. Owners may also use chromium 
supplements for insulin resistant horses as it has been shown to increase mRNA 
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expression of insulin and GLUT4 receptors in the skeletal muscle of mice 
[40]
. 
Pioglitazone, an insulin sensitizing drug used in humans, was recently investigated for 
use in horses, but no significant improvement in insulin sensitivity was detected 
[41]
. 
 Due to a lack of proven pharmaceutical therapies available for metabolic 
syndrome the most effective treatment for affected horses is intense management. As 
with humans, the best treatment to improve insulin sensitivity is through dietary 
restriction and increased exercise 
[42]
. Limiting intake of feeds high in nonstructural 
carbohydrates will avoid sharp increases in plasma insulin concentrations and, 
therefore, the development or aggravation of insulin resistance 
[43]
. This will also help 
shorten the insulin refractory time during which hyperglycemia is present 
[4]
. Moderate 
exercise alone without concurrent adjustment to diet was shown to be ineffective in 
reducing insulin levels in obese individuals 
[33]
. However, the combination of diet 
control and exercise was successful in lowering insulin levels and bodyweight 
[15]
, 
though results varied by individual. 
Hypothyroidism and Thyroid Function in EMS horses 
Horses affected by EMS are often incorrectly diagnosed as having 
hypothyroidism as these animals tend to have lower circulating thyroid hormone levels 
[44]
. However, thyroidectomized horses do not show the clinical signs of regional 
adiposity and laminitis seen in EMS affected individuals 
[45, 46]
.  Levothyroxine is 
often prescribed for EMS affected horses to improve insulin sensitivity as pretreatment 
of horses with levothyroxine has been shown to prevent the development of 
endotoxemia-induced insulin resistance 
[47]
. Levothyroxine may also be administered 
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to raise the basal metabolic rate and help “jump start” weight loss in horses that are 
currently affected by laminitis where an exercise regimen cannot be implemented.  
Equine Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) 
Equine Pituitary Pars Intermedia Dysfunction (PPID), also commonly referred 
to as Equine Cushing’s Disease [48], is the most common endocrinopathy in late 
middle-aged and geriatric horses 
[49]
. PPID results in increased production of 
proopiomelanocortin (POMC) derived peptides due to the loss of dopaminergic 
inhibition from the hypothalamus 
[50-53]
. POMC is further processed into 
adrenocorticotropic hormone (ACTH), corticotrophin-like intermediate lobe peptide 
(CLIP), melanocyte-stimulating hormone (MSH), β-endorphin and β-lipotropin [49]. 
Most PPID affected horses develop a pituitary adenoma or show signs of adenomatous 
hyperplasia 
[54, 55]
. Originally, it was believed that the adenoma itself was rather 
inactive and it was the encroachment of the tumor on the hypothalamus that accounted 
for the clinical signs of Cushing’s Disease [56]. However, it has been shown that this 
hyperplasia is responsible for increased circulating levels of ACTH 
[57]
 and β-
endorphins 
[58]
. These horses may also develop adrenal hyperplasia 
[55]
 and, in turn, 
hyperadrenocorticism. Though rare, some cases of pituitary independent Cushing’s 
syndrome have been reported in the horse 
[59]
. 
 The pars intermedia, consisting of melanotropes, is under the direct inhibitory 
control of dopamine secreted by the periventricular neurons of the hypothalamus 
[60]
. 
McFarlane et al., using tyrosine hydroxylase staining, found that the expression of 
dopamine in PPID horses was only 20% of the levels expressed in younger and age-
matched controls 
[53]
. These results are in agreement with a previous study that found 
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dopamine levels to be decreased 88% in PPID affected horses 
[58]
. Knockout mice 
deficient in dopamine D2 receptors (expressed in the pars intermedia) show selective 
proliferation of the melanotropes of the intermediate lobe which then double their 
POMC mRNA expression 
[61]
. There is also alternative processing of POMC within 
melanotropes with increased expression of prohormone convertase 1 which, in turn, 
increases levels of ACTH 
[61]
. Further, it was found that corticotropin-releasing factor, 
the releasing factor that stimulates corticotropes and melanotropes via the 
paraventricular nucleus 
[62]
, is not responsible for the increased POMC synthesis 
[61]
. 
PPID shares many clinical signs with EMS including regional adiposity and a 
predisposition to laminitis 
[63]
. The most obvious clinical sign of a PPID affected 
individual is abnormal hair coat which can manifest as hirsutism, delayed coat 
shedding or incomplete shedding 
[64, 65]
.Though the exact mechanism by which horses 
develop hirsutism is not understood, this sign has been shown to have a positive 
predictive value of 90% for PPID 
[66]
. Mares may also display an abnormal estrus 
cycle 
[63]
. PPID has a mean age of onset of 20 years 
[65, 67]
, though cases have been 
noted as young as 7 years 
[54]
. A correlation has been shown between age and plasma 
cortisol and ACTH concentrations in healthy horses which suggests that age may be a 
predisposing factor for PPID 
[68]
. Other signs of PPID include polyuria, polydipsia and 
muscle wasting 
[49]
. 
Seasonal variation in plasma ACTH concentration have been shown with 
higher levels in the autumn 
[22, 28, 68]
, though the timing and duration of this elevation 
does not differ between PPID affected horses and healthy horses 
[69]
. This seasonal 
increase is thought to help prepare the horse metabolically for lean winter months 
[70]
. 
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It has been reported that ponies have a lower plasma ACTH concentration than horses 
[51]
, but Donaldson et al. showed that there is no significant difference in ACTH levels 
between healthy horses and ponies 
[68]
. 
Equine Pituitary Pars Intermedia Dysfunction Diagnostic Testing 
A popular method for detecting PPID in horses is the dexamethasone 
suppression test (DST). This test requires plasma cortisol concentrations to be 
measured from blood samples drawn before and 19 hours after intramuscular 
administration of dexamethasone 
[48]
. Horses affected by PPID will fail to suppress 
cortisol levels below 1 ug/dL 
[66]
. Though it was first reported that the DST has 100% 
sensitivity and specificity 
[48]
, it has since been shown that the specificity may be 
closer to 76% and sensitivity to 65% 
[66]
. The test is less accurate during the seasonal 
ACTH increase in the autumn, and the pituitary axis in older horses is less sensitive to 
dexamethasone administration 
[68]
. There is also concern that the administration of 
dexamethasone can exacerbate laminitis in horses with current or previous bouts of 
laminitis 
[48, 49]
, although no laminitis was observed in a study using the DST 
[48]
. 
Another complication of the dexamethasone suppression test is the need for multiple 
blood draws and the additional cost incurred by the owner. A cheaper option is 
needed, especially if there is a need for multiple testing throughout the year. 
Another popular diagnostic test for PPID is to measure baseline plasma ACTH 
levels. ACTH is one of the POMC-derived peptides that is over expressed by 
melanotropes in PPID affected horses 
[61]
. ACTH levels are elevated in PPID affected 
horses when compared to healthy controls 
[51, 67, 69]
. This test requires a single blood 
draw 
[51]
 for plasma and is tested using a chemiluminescent ACTH immunoassay 
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validated specifically for equine plasma 
[71]
. Reported reference values have varied 
between 35 pg/mL 
[28, 51]
, 50 pg/mL 
[72]
 and – 70 pg/mL [15], though the 35 pg/mL 
cutoff seems to be used most often in clinical practice 
[22]
. Testing for endogenous 
ACTH also faces complications due to seasonal fluctuations as both PPID affected and 
normal horses reach their highest plasma concentrations in the autumn from August to 
October 
[28, 69]
, though the total percent increase in ACTH concentration is greater in 
PPID horses 
[28]
.  It has been proposed that a separate reference range for ACTH levels 
may be established for PPID affected horses in the autumn 
[69]
. ACTH levels may also 
fluctuate throughout the year in response to stresses such as laminitis 
[73]
 and 
transportation 
[74]
. However, baseline plasma ACTH levels are still advantageous over 
dexamethasone suppression tests, especially if repeated testing is needed to calibrate 
medication, because only a single blood draw and, therefore, a single veterinarian visit 
is required. While a single elevated endogenous ACTH level may be indicative of 
PPID, it may be more informative to test throughout the year to make an accurate 
diagnosis 
[75]
.   
α-MSH, a POMC-derived peptide, has been investigated as another potential 
diagnostic marker for PPID 
[28]. αMSH suffers the same problem as ACTH in that 
levels are elevated during the autumn in both horses and ponies 
[76]. α-MSH shows a 
correlation with body mass index 
[77]
 and may not be an accurate diagnostic tool for 
horses that have lost body condition due to muscle wasting.  There may also be a need 
for separate reference values based on breed as one study has shown an 11-fold 
seasonal increase in α-MSH in horses as compared to a 2-fold higher level in ponies 
[76]
. Though it makes intuitive sense to measure cortisol concentrations to diagnose 
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PPID, cortisol levels are variable in PPID horses 
[48]
 and therefore does not make a 
reliable diagnostic test.  
Treatments for PPID 
Some of the most effective treatments currently available to owners of PPID 
affected horses are pergolide, cyproheptadine and trilostane 
[71, 78-80]
. Pergolide is a 
dopamine agonist that acts to replace the action of the damaged dopaminergic neurons 
of the hypothalamus. Pergolide was evaluated as a treatment for Parkinson’s Disease 
in humans 
[81]
. In PPID affected horses, it reduces plasma ACTH concentrations 
[15, 71, 
82]
.  Cyproheptaine, a serotonin antagonist, is less effective in terms of improving 
clinical signs of PPID when compared with pergolide 
[82]
. A complication associated 
with pergolide is that dosing is difficult because severity of PPID may not be 
determined until post mortem examination of the pituitary and, even then, it is still not 
definitive 
[83]
. Repeated baseline ACTH levels may need to be drawn to help assess the 
effectiveness of the treatment. It has yet to be determined if pergolide arrests the 
hyperplasia of the pituitary, though this is likely dose dependent. 
Trilostane is a competitive inhibitor of the 3β-hydroxysteroid dehydrogenase. 
Widely used as a therapy for hyperadrenocorticism in dogs 
[84]
 and shown to be 
effective in horses 
[79]
, it acts to decrease circulating cortisol levels. It may not be the 
best treatment because, as mentioned above, cortisol levels are not always elevated in 
PPID affected horses. Also, trilostane does not control the hyperplasia of the pars 
intermedia. Pergolide is the better treatment because it likely also restores the balance 
of all POMC-derived peptides which may account for all of the symptoms where 
trilostane will only help control any phenotypic changes due to cortisol. PPID affected 
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horses would likely benefit from the same management of diet and exercise as EMS 
horses to help reduce obesity. 
Identifying Genetic Predispostions 
Though no specific genetic predispositions for EMS or ECD have been 
identified, breed differences have been noted in previous studies, with ponies 
frequently observed as particularly predisposed to both conditions 
[4, 65, 85-87]
. Ponies 
have higher circulating levels of insulin when compared to horses 
[85, 88]
 and there is a 
notable difference in insulin sensitivity across breeds 
[88]
. There may also be interplay 
between EMS and PPID, with PPID predisposing to hyperinsulinemia 
[15, 89, 90]
. 
However Frank et al. has shown that mean insulin levels do not differ between PPID 
and normal horses and hyperinsulinemia was not observed after overnight stall 
confinement 
[69]
. EMS horses have the same seasonal ACTH pattern as normal horses 
[22]
 which shows that EMS can develop independent of PPID. However, the overlap of 
clinical signs between these two conditions and the possible mechanisms that may 
predispose one condition to another warrants investigation of both conditions for 
possible genetic predispositions.
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CHAPTER 2 
Original research 
Background 
 The two most common conditions leading to endocrinopathic laminitis in the 
horse are equine metabolic syndrome (EMS) and equine Cushing’s Disease (ECD), 
also known as pituitary pars intermedia dysfunction (PPID) 
[1]
. Both of these 
conditions present similar clinical signs such as regional adiposity. It has been 
suggested that one condition may predispose to the other as high plasma 
concentrations of both insulin and ACTH in the same individual are frequently 
observed. Though no specific genetic predispositions to either condition have been 
identified, a difference in the prevalence of either condition across breeds suggests a 
genetic link. 
 PPID results from the loss of dopaminergic inhibition from the neurons of the 
periventricular nucleus 
[2]
 leading to increased production of proopiomelanocortin and, 
subsequently, ACTH. The mean age of onset for PPID is 20 years 
[3, 4]
 but cases have 
been observed in individuals as young as 7 years old 
[5]
. An abnormal hair coat is the 
most obvious clinical sign of PPID 
[4]
 and is not observed in EMS affected horses. 
When diagnosing PPID the dexamethasone suppression test is considered the gold 
standard, though it is not reliable during the seasonal ACTH increase of autumn 
[6]
. 
Endogenous plasma ACTH levels are preferable to the dexamethasone suppression 
test because only one plasma sample is needed, but it also is not a reliable 
measurement during the autumn 
[7, 8]
. 
The key clinical signs of EMS (previously referred to as Peripheral Cushing’s 
Disease) are regional adiposity, often presenting as a “cresty” neck, insulin resistance 
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characterized by hyperinsulinemia and a history of laminitis 
[9]
. The average age of 
onset for EMS horses is slightly younger than that of PPID with ages often ranging 
from 8-18 years 
[9]
. Diagnostic testing available for EMS include labor intensive 
methods such as the frequently sampled intravenous glucose tolerance test, the 
combined glucose insulin test and the euglycemic-hyperinsulinemic clamp technique. 
For clinical applications, it is simplest to draw a single blood sample and measure the 
fasted plasma insulin concentration to detect hyperinsulinemia.  
Currently, there are few pharmacological options available to treat PPID or 
EMS affected horses. PPID is often successfully managed using the dopamine agonist 
pergolide, but it is usually given daily and dosage varies from 0.5 mg to 5 mg. At 
these dosages pergolide is an expensive option. Cyproheptadine, a serotonin 
antagonist, and trilostane, an inhibitor of β-hydroxysteroid dehydrogenase, are 
alternative treatments, but pergolide remains the most effective medication available. 
EMS horses have very limited pharmacological treatment options when considering 
insulin-sensitizing drugs. Responses to metformin treatment in EMS affected 
individuals have been mixed, possibly due to limited bioavailability of this drug in the 
horse. 
The interaction between EMS and PPID has yet to be determined. Although 
PPID affected horses are often observed to also have hyperinsulinemia 
[10-12]
, Frank et 
al. showed that mean insulin levels do not differ between PPID and control horses and 
hyperinsulinemia was not observed after overnight stall confinement 
[13]
. In addition, 
horses are able to maintain normal ACTH concentrations and seasonal patterns in the 
presence of hyperinsulinemia 
[7]
. However, the frequent observation of concurrent 
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elevated plasma concentrations in both insulin and ACTH indicates that these 
conditions may predispose an individual to develop the other condition.  
The differences observed in the frequency of either PPID or EMS across 
breeds indicates that there may be a genetic component to either condition. Treiber et 
al. suggest a dominant mode of inheritance for laminitis in individuals with EMS 
[14]
, 
though the research herd for that study consisted exclusively of ponies and the 
methods of pedigree analysis were not made available. Differences in the rate of 
elevated plasma concentrations of ACTH, an indication of PPID, and insulin, an 
indication of EMS, across different breeds shows that ponies, Morgans and Arabians 
have the highest frequencies of hyperinsulinemia while Thoroughbreds and Quarter 
Horses rank amongst the lowest frequencies (Streeter et al., unpublished data). This is 
consistent with previous observations that ponies and Morgans are at a higher risk for 
EMS 
[15]
. Arabians were chosen as the target breed for this study due to their moderate 
frequency of EMS and PPID as well as their large population and, consequently, ease 
of obtaining DNA samples in sufficient quantity for the study. Furthermore, any 
candidate genes identified in this study can be investigated in Arabian-derived breeds 
with low disease frequencies, such as the Quarter Horse and Thoroughbred that may 
have lost genetic predispositions to both conditions. 
The objective of this study is to conduct a genome-wide association to identify 
candidate genes associated with EMS, PPID or both conditions within the Arabian 
breed using the EquineSNP50 chip. The EquineSNP50 chip has been used 
successfully to identify candidate genes for single gene diseases 
[16]
 as well as likely 
polygenic traits 
[17]
.  
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Materials and Methods 
 Horses – Horses were recruited for this study based on endocrinology records 
from Cornell University College of Veterinary Medicine’s Animal Health Diagnostic 
Center. Owners were contacted and asked to submit a brief health history 
accompanied by a blood or hair sample. A total of sixty-five samples from Arabian 
horses were obtained for this study. All but five horses were confirmed to be of full 
Arabian ancestry based on registration records. Of the five individuals that were not 
confirmed to be full Arabians, all were anecdotally reported to be of full or a majority 
of Arabian descent although registration papers were not available. Ages, based on 
known ages at the time of the blood draw, ranged from 11 to 30 years. The mean ages 
for the disease categories Both, EMS, PPID, Normal and were 25.0, 18.6, 22.8, and 
19.4 years, respectively. The group consisted of 32 geldings, 30 mares and 3 stallions.  
 Classification – Classification of horses was adapted from Walsh et al. into 
PPID (P), EMS (M), Normal (N) and an additional Both (B) group 
[11]
. Horses with 
ACTH levels greater than 70 pg/mL and insulin levels less than 40 uIU/mL were 
designated “PPID” while horses with insulin levels > 70 uIU/mL and ACTH levels 
<40 pg/mL were designated “EMS”. Horses with ACTH and insulin levels <40 pg/mL 
or uIU/mL, respectively, were considered “Normal” and those with both levels > 70 
were grouped into the fourth category termed “Both”. Individuals with levels between 
40 and 70 were omitted as uncertainty in reference ranges made it difficult to assign 
those individuals to a disease category. Horses currently on medications were 
evaluated based on endocrinology results prior to starting medication. Horses with 
elevated levels for both insulin and ACTH were assigned to either the EMS or PPID 
groups if previous endocrinology testing was available to indicate which condition 
developed first. Levels taken between the months of August and October were not 
used to determine disease status due to the seasonal increase in plasma ACTH levels 
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[7]
. The total number of individuals in each group for Both, EMS, PPID and Normal 
were 9, 15, 24 and 17, respectively. 
 DNA extraction and genotyping – Blood samples were extracted using the 
Gentra Puregene Blood Kit (Qiagen Inc, Valencia, CA, USA) using the 
manufacturer’s protocol for whole blood. Hair samples were extracted using an 
adapted whole blood protocol starting with 15 hair bulbs incubated overnight at 65
o
C 
in 100 µL of lysis buffer [1% Tween 20, 1X PCR buffer (Applied Biosystems, Foster 
City, CA, USA), 2.5mM MgCl2] containing 2 µg Proteinase K. The extraction was 
completed following the manufacturer’s protocol. A total of 500 ng of each DNA 
sample was sent for SNP genotyping at GeneSeek (Lincoln, NE, USA) where 
Illumina’s Infinium® II Assay (Illumina Inc, San Diego, CA, USA) was performed on 
the EquineSNP 50 Genotyping BeadChip (Illumina Inc, San Diego, CA, USA) 
containing 54,602 SNPs. The EquineSNP 50 BeadChip SNPs were derived from the 
EquCab2.0 assembly with an average spacing of 43.2 kb across the genome. 
 Statistical Analysis – Statistical analyses were performed using the PLINK 
v1.07 Whole genome association analysis toolset 
[18]
 and JMP 8.0 (SAS Insitute Inc, 
Cary, NC, USA). Basic association (chi-square) tests were used to compare disease 
cases and controls. Since it is unknown whether there are common genetic 
predisposing factors between EMS and PPID or if they develop independently, various 
groupings of the disease and control categories were used to develop a total of 15 
qualitative associations. Quantitative associations were also performed for highest 
recorded ACTH (excluding August-October measurements) and insulin levels. An 
additional association was performed comparing horses with at least one episode of 
laminitis versus those with no recorded history of laminitis, regardless of disease 
category. SNPs with a missing genotype rate greater than 10% were excluded from 
analysis. SNPs in linkage disequilibrium (r
2 
> 0.99) were pruned to a single SNP per 
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haplotype block in all graphs. P-values unadjusted for multiple testing are reported and 
the Bonferroni corrected α level is shown where appropriate. Overall study α level is 
5%. Any SNPs exceeding the significance threshold for multiple testing were mapped 
on the UCSC Genome Browser 
[19]
 using the September 2007 assembly (EquCab2.0) 
of the horse genome. Candidate genes were identified within ~50 kb of each 
significant SNP. 
Results 
A total of 68 SNPs representing 59 different loci exceeded the significance 
threshold after correction for multiple testing. When performing a quantitative 
association with the highest ACTH level recorded for each individual, SNP BIEC2-
215377 (ECA 13) was the most significant SNP with a P-value of 4.34 e-7 (Figure 
2.1). Two additional significant SNPs, BIEC2-377685 (ECA17) and BIEC2-1007280 
(ECA 7) with P-values of 3.55 e-6 and 2.4 e-5, respectively, were also found. XPO6 
was the only candidate gene identified within 50 kb of SNP BIEC2-215377 (ECA13). 
Candidate genes identified for BIEC-1007280 (ECA7) include OLFML1, SYT9 and 
PPFIBP2. No candidate genes were identified for BIEC2-377685 (ECA17).  
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Figure 2.1 Quantitative association of highest recorded ACTH value. Association of 
38,315 independent SNPS with –log10P-value on the y-axis and SNP, sorted and color-
coded by chromosome, on the x-axis. Reference line included to show the significance 
threshold for multiple testing. Three significant SNPs are shown, including the most 
significant SNP, SNP BIEC2-215377 (ECA13) with a P-value of 4.34 e-7. 
 
The SNP BIEC2-173131 (ECA12) achieved the second best P-value (1.48 e-6) 
of all associations in the quantitative association of the highest recorded insulin. This 
association also gave the greatest number of significant SNPs for a single association 
with a total of 38 SNPs representing 30 different loci (Figure 2.2).  Candidate genes 
found for BIEC2-173131 include ALX4 and PRRX2. 
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Figure 2.2 Quantitative association of highest recorded insulin value. Association of 
38,343 independent SNPS with –log10P-value on the y-axis and SNP, sorted and color-
coded by chromosome, on the x-axis. Reference line included to show the significance 
threshold for multiple testing. A total of 38 SNPs representing 30 loci exceeded the 
significance threshold. 
 
Manhattan plots for each association and a table of all significant SNPs can be 
found in the Appendix. Any SNPs that do not exceed the significance threshold but 
deviate from expected P-values, as demonstrated by a quantile-quantile plot, may be 
worth further investigation. Also of particular interest are those SNPs with candidate 
genes that have been previously associated with obesity, diabetes and/or insulin 
resistance. A Manhattan plot of BM vs. N shows only one significant SNP, BIEC2-
596175 (ECA22) (Figure 2.3). The SNP with the second smallest P-value, BIEC2-
770354 (ECA3) approaches but does not exceed the significance threshold for 
multiple testing.  
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Figure 2.3 Qualitative association of hyperinsulinemia (B or M) vs. controls (N). 
Association of 37,647 independent SNPS with –log10P-value on the y-axis and SNP, 
sorted and color-coded by chromosome, on the x-axis. Reference line included to 
show the significance threshold for multiple testing.  
 
Two candidate genes, FTO and ATP5H, were identified for BIEC2-770354 
(ECA3) and its neighboring SNP in linkage disequilibrium, BIEC2-770355.  Both 
SNPs are located within 500 bp of each other and are found in the intron of FTO in the 
human, mouse and cow. These two SNPs also deviate from expected –log10 P-values 
in the association BMP vs. N with a P-value of 1.03 e-4 (Figure 2.4). 
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Figure 2.4 Quantile-quantile plot of qualitative association of all disease groups (B, M 
and P) vs. controls (N). The actual –log10 P-value is plotted on the y-axis with the 
expected –log10 P-value plotted on the x-axis. 
 
Another candidate gene, attractin-like 1 (ATRNL1), was found in the 
association M vs. N. Two SNPs, BIEC2-7588 (ECA1) and BIEC2-7581 (ECA1), 
located within 7 kb of the first intron of ATRNL1 did not exceed the significance 
threshold but did deviate from expected –log10 P-value with P-values of 1.01 e-4 and. 
1.26 e-4, respectively.  
Discussion 
The lack of affordable and effective treatments for both EMS and PPID 
combined with the evidence of possible genetic predispositions to both conditions 
warrants further investigation into the heritable components of both disorders. 
Identification of the genetic underpinnings of EMS and PPID allows for a better 
understanding of how both conditions arise and if alternative therapies can be 
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developed.  This genome-wide association study has identified several interesting 
candidate genes previously linked to obesity, diabetes and/or insulin resistance in 
humans and other animals. The most intriguing candidate is the fat mass and obesity 
associated gene or FTO. Fto was first identified in the rat by Peters et al. who 
designated it “fatso” due to its large, 250 kb sequence length [20]. This proved to be 
very serendipitous naming as FTO was first recognized as a predisposing factor to 
obesity in a genome-wide association study looking for genes associated with type II 
diabetes in humans 
[21]
. Frayling et al. found that SNPs within the first intron of FTO 
were associated with type II diabetes through an effect on body mass index 
[21]
. Since 
that original paper FTO variants have been associated with obesity in a wide variety of 
populations 
[22-24]
. Though the function of FTO is not known, there have been many 
studies attempting to elucidate the mechanism of how FTO predisposes individuals to 
obesity. FTO expression is increased in the skeletal muscle of type II diabetic patients 
[25]
 as well as in the subcutaneous adipose tissue of obese individuals 
[26]
. Murine Fto 
has been shown to increase feed intake and, therefore, increase obesity regardless of 
diet type 
[27]
. Furthermore, this same study showed that a lack of Fto function results 
in a lean phenotype in mice 
[27]
.  
FTO is an excellent candidate gene to investigate in both EMS and PPID 
affected horses due to the link with body mass index. The gene is highly conserved 
across all vertebrate species including teleost fish suggesting a history in vertebrate 
evolution of over 450 million years 
[28]
. It is also worthy to note that, in the rat, Fto 
expression is detected in the paraventricular nucleus and is up regulated in the 
hypothalamus in response to 48 hours of food deprivation 
[28]
. The exact mechanism 
32 
by which FTO regulates feed intake is unknown; therefore, if FTO is capable of 
regulating feed intake in PPID affected horses in the face of degeneration of the 
dopaminergic neurons of the paraventricular nucleus this may suggest a pathway 
independent of the innervation of the pars intermedia. FTO shows its best P-value in 
the association where all metabolic conditions are considered (p = 4.16 e-5, ECA3 
6.5Mb). As the Both and EMS categories share this common locus, this suggests a 
genetic predisposition to EMS followed by PPID.  
The SNP with the second most significant P-value, BIEC2-173131, yielded 
two candidate genes, ALX4 and PRRX2. In a genome wide association study to 
identify loci associated with type II diabetes in humans, Sladek et al. identified ALX4 
as a candidate gene 
[29]
. This study used stringent selection criteria to enrich for risk 
alleles associated with type II diabetes. The first cohort required individuals to have at 
least one affected first degree relative with type II diabetes. Individuals also had a 
lower body mass index to help select for alleles that predispose to insulin resistance 
through a pathway independent of obesity. A second cohort with relaxed inclusion 
criteria were then tested to confirm significant loci identified in the first stage. Though 
no SNPs were identified within ALX4, three SNPs were found within EXT2 in the 
same haplotype block. ALX4 is an interesting candidate gene as it was found 
independent of excessive body mass index in the first cohort. Due to insufficient 
information concerning weight and body measurements, it would be difficult to assess 
the relation of ALX4 to hyperinsulinemia independent of obesity in the present study. 
However investigation of ALX4 in an experimental herd of hyperinsulinemic and 
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control horses with varying levels of obesity may show an association similar to that 
found in humans. 
Another top candidate gene from this dataset (p = 1.01 e-4) is attractin-like 1 
or ATRNL-1. Attractin, a transmembrane protein product of the Mahogany gene 
[30]
, is 
believed to act as a co-receptor with the melanocortin 1 receptor (MC1R) for agouti, 
[31]
. Attractin-like protein (ALP), unlike attractin, is able to interact directly with the 
MC4R C-terminus 
[32]
. ALP has high expression in brain, kidney, heart lung and liver, 
overlapping with some of the same brain sites where MC4R mRNA is expressed 
[32]
. It 
has been suggested that attractin has a protective role in the face of oxidative stress in 
the rat 
[33]
 and that attractin and ALP may have redundant roles 
[34]
. This evidence 
makes a case for a possible role for ATRNL-1 in protection of individuals from the 
oxidative stress associated with obesity and, in consequence, protection from the 
development of the neuronal degeneration associated with PPID. Notably, ALP null 
mice do not seem to show any abnormalities due to the possible redundancy with 
attractin 
[34]
, so any SNPs associated with ATRNL-1 that result in loss-of-function 
would likely not result in obesity. However, if a SNP within ATRNL-1 were associated 
with an altered form of ALP that antagonizes MC4R, then obesity may result. 
MC4R has been extensively researched for its role in obesity in a variety of 
animals. MC4R normally acts to regulate energy homeostasis and food intake. 
Endogenous agonists for MC4R include the melanocyte-stimulating hormones derived 
from POMC, with β-MSH having the highest affinity [35]. Agouti-related protein 
(AgRP), an antagonist of MC4R, induces increased food intake 
[36]
 and prolonged 
antagonism of MC4R results in hyperphagia and obesity in rats 
[37]
. MC4R has also 
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been associated with elevated insulin and glucose levels 
[38]
. However, the obesity and 
metabolic syndrome associated with MC4R dysfunction was shown to be overcome 
through exercise in MC4R knockout mice 
[39]
. This suggests that mutations of 
ATRNL-1 that affect its interaction with MC4R may possibly be overcome through 
environmental control rather than pharmacological intervention. MC4R itself failed to 
be significantly associated with either EMS or PPID. POMC would also be a likely 
candidate gene based on its association with PPID and MC4R mutations, but its 
closest SNP is located over 30 kb away and therefore may not be sufficiently covered 
by this panel of markers. 
The results of this study are very encouraging with several quality candidate 
genes. However, further refinement of this study is needed to identify the strongest 
candidates. A major problem confronted by this study is the relatively limited 
coverage of SNPs across the horse genome. Comparable SNP chips for cows and 
humans represent over 500,000 and 1 million loci, respectively. As previously 
mentioned, several top candidate genes based on current literature, such as POMC, 
coverage was too sparse at those loci and significant associations in these genes may 
have been missed. This problem can only be overcome with the development of 
improved SNP chips with better coverage.  
Another problem inherent in genome-wide association studies is that complex 
traits can be the result of many subtle genetic alterations that must come together to 
develop the disease. Individual alterations may confer a low to moderate risk of 
developing the disease, but it is the cumulative effect of these alterations that will 
bring about the phenotype of interest. A basic genome-wide association study, 
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however, is based on generating P-values for individual SNPs, so SNPs associated 
with low to moderate risk factors may not be distributed in the population in such a 
way that significance is detected. It is more likely that an individual that is considered 
unaffected will carry a mutation that confers a low to moderate effect if they do not 
carry other risk factors, therefore, the chi square statistic for that particular SNP will 
not be as extreme and significance will not be detected. Alternatively, a SNP 
conferring low to moderate risk may have a higher frequency in the diseased group 
and may exceed the significance threshold. However, this SNP may still need the 
cumulative effect of other risk factors to bring about the disease and, therefore, its 
predictive power will be overestimated. Complex statistical methods for deciphering 
patterns of epistasis are still in development and may clarify these relationships in the 
future. 
A vital part of any genome-wide association study is the correct classification 
of the affected/disease cases versus the unaffected/control cases. Rare, monogenic 
diseases may be easier to assign a status to, as in the case of Lavender Foal Syndrome 
[16]
, but likely polygenic traits, such as EMS and PPID where several genes are 
interacting, are more difficult to properly assign to a category. Some of this difficulty 
lies in the ability to acquire complete health histories and uniform diagnostic testing. 
For example, the form of laminitis typically associated with both EMS and PPID is 
insidious and may not be recognized until postmortem examination. Some owners 
may not have noted a history of laminitis when in fact the horse was suffering from 
low grade laminitis without any clinical signs. Therefore, a lack of significant hits 
within the laminitis association is likely due to miscategorization of unaffected 
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individuals. This problem of incorrect assignment to a category may be overcome by 
increasing the number of horses in the study. In the case of Lavender Foal Syndrome, 
a monogenic disease, 36 individuals (6 affected and 30 unaffected) were needed to 
generate 14 significant SNPs. A complex trait with low to moderate risk factors will 
likely need more than a total of 65 samples in order to produce many significant hits. 
Adding more individuals will help to dilute the effect of incorrectly assigning a few 
individuals in the overall study.  
Further complicating the matter of correctly assigning individuals to disease 
categories is the influence of environmental factors such as diet and exercise. 
Individuals with genetic predispositions that put them at a low risk of developing EMS 
may develop the disease if they are put on a diet high in nonstructural carbohydrates. 
Diets high in nonstructural carbohydrates can lead to repeated bouts of postprandial 
hyperinsulinemia and, subsequently, insulin resistance 
[40, 41]
. While general dietary 
information was provided for the individuals in this study, estimation of total 
nonstructural carbohydrates intake was difficult to determine. Some individuals had 
switched diets after being diagnosed with EMS and dietary information leading up to 
diagnosis was not available. Many individuals in this study were not routinely 
exercised and were kept on pasture at all times. A lack of physical activity can put 
individuals with low genetic predispositions at a higher risk for developing insulin 
resistance 
[42]
. Another factor affecting miscategorization is the age of onset, especially 
for PPID. With the mean age of onset for PPID being 20 years, it may not be 
appropriate to use younger horses as controls as they may still yet develop the disease. 
The mean age of the control group in this study was within the mean age range of the 
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disease categories, but older controls may be more appropriate to use to minimize 
miscategorization. In addition, some EMS horses may go on to develop PPID and be 
assigned to the Both category. However, it is more beneficial to identify the first 
condition that develops to help separate genetic predispositions to one disease or the 
other. Any common genetic predispositions between EMS and PPID can be found by 
combining the two groups as one disease category in basic associations. 
It is also important to assess the practical applications of this study for the 
common horse owner. While the mechanisms of the development of both PPID and 
EMS are of interest to researchers, the value for horse owners will be derived from 
new preventative management practices. As quoted from the ACVIM Consensus 
Statement “EMS is a complex disorder for which there are more questions than 
answers at present” [43]. As information becomes available to researchers about how to 
properly characterize EMS and PPID, these developments need to be transferred to 
owners to help identify more affected individuals and increase awareness of both 
disorders.  
The prevalence of obesity in horses is difficult to estimate as studies conducted 
through owner-based reporting show bias towards lower obesity scores 
[44]
. 
Stephenson et al. found a prevalence of obesity in leisure horses in the UK of 20.6%, 
which is less than the 45% reported in a study of horses in Scotland 
[45]
. This same 
study also found that when 15 randomly selected horses from the study were visited 
by researchers trained in assessing body condition scores, the mean score assigned by 
researcher was significantly higher than that assigned by the owner. Further, eight 
owners assigned a body condition score a full point below that of the researcher. When 
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this error rate was extrapolated to the questionnaire data the percentage of obesity 
more than doubled to 54.1%. It may be that owners are not properly trained to assign 
body condition scores or, more likely, owners have misconceptions of what constitutes 
a “healthy” weight for a horse. The muscle wasting seen in PPID affected horses can 
be confused with the loss of body condition sometimes seen in older horses 
[46]
. In an 
attempt to avoid weight loss in geriatric horses owners will supplement the diet of 
their horse above their nutritional needs which may result in obesity and, 
consequently, insulin resistance and laminitis. It is necessary to educate owners on 
how to properly assess and maintain an appropriate body condition, especially in the 
geriatric horse that is at a higher risk of EMS and PPID.  
Early detection is very important to avoid laminitis associated with both PPID 
and EMS. However, early detection is complicated by the fact that clinical signs of 
both EMS and PPID may be seen much later than the actual onset of either condition. 
Older horses show decreased sensitivity to the dexamethasone suppression test in the 
absence of other clinical sign of PPID 
[6]
. Therefore, it can be difficult to determine the 
precise onset of PPID in the geriatric horse. It is unknown what extent of pituitary 
hyperplasia or duration of endogenous ACTH elevation is required to bring about 
clinical signs of PPID as the mechanisms of most of these signs remain unknown. 
There is considerable overlap of clinical and histological findings between PPID 
affected and healthy aged controls 
[47, 48]
which makes correct diagnosis of PPID, 
especially early on in the disease, difficult for clinicians. 
The identification of genetic predispositions to both EMS and PPID may allow 
horses to be used as models for the development of metabolic syndrome and 
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Parkinson’s disease in humans. Parkinson’s disease results from the degeneration of 
dopaminergic neurons of the substantia nigra 
[49]
. Pergolide, the most effective 
treatment available for PPID, is still being investigated as a treatment for Parkinson’s 
disease 
[50]
.  The horse offers a model for spontaneous dopaminergic 
neurodegeneration with PPID. By identifying the genetic predispositions associated 
with PPID in horses, researchers may be able to look for these same predispositions in 
humans and elucidate the subtle pathways that lead to Parkinson’s in humans.  
PPID is also very important to study because it cannot be cured at present. 
Pergolide is an effective pharmacological intervention, but it has not yet been shown 
to shrink or even arrest the hyperplasia of the pars intermedia. Medication must be 
administered for the rest of the horse’s life. Surgery is not a practical solution for most 
horse owners, so control of environmental factors or being able to breed the 
predisposition out of the horse would be more effective. The late onset of PPID also 
means that owners are less likely to invest in costly solutions unless that particular 
horse still has value for breeding or performance.  
The horse also poses as an interesting model for metabolic syndrome in 
humans as horses normally lack hyperglycemia in the presence of hyperinsulinemia. 
There may be genetic protective measures in the horse that prevents failure of the 
pancreatic β cells or it may simply be due to the horse’s shortened lifespan relative to 
humans. The characteristic regional adiposity that confers a higher risk factor for 
developing laminitis is similar to the accumulation of abdominal fat seen in humans 
developing metabolic syndrome. Again, the ability to selectively breed against 
predispositions in the horse can be beneficial for breeders, but EMS may be controlled 
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by environmental factors. Although insulin resistance may be reversible through 
intense management, it is difficult to implement a program on previously laminitic 
individuals.  The identification of genetic predispositions will allow owners to identify 
high risk individuals at birth and manage their diet and exercise regimen appropriately 
before the onset of disease. 
The identification of genetic predispositions to EMS and/or PPID is a 
necessary step toward developing better diagnostic tests for at risk individuals and 
better therapies for those affected. The candidate genes identified in this study, 
especially those previously associated with obesity and insulin resistance, are worthy 
of further fine mapping. These candidate genes should be investigated in both 
Arabians and Arabian-derived breeds with low disease frequencies, such as the 
Thoroughbred and Quarter Horse. The addition of more individuals, both affected and 
older controls, will also help strengthen the power of the associations and identify 
more candidate genes. The dataset can also be improved with expanded marker panels 
(SNP chips) with better coverage across the genome. This study is limited by the 
information currently available concerning diagnosis and pathophysiology of EMS 
and PPID. The development of more diagnostic tests for other parameters will help 
classify affected individuals into their appropriate disease category. Finally, 
identification of genetic predispositions to EMS and PPID will allow owners to breed 
these predispositions out of their herds and provide better treatment options to those 
individuals already affected by either condition.
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 APPENDIX 
For each phenotypic classification association statistics were calculated. Notable 
associations were discussed in the main body of this work. For comparison, results from all 
calculations are shown below. All Manhattan plots have a reference line to show the significance 
threshold for multiple testing. 
 
Supplemental Figure 1: Manhattan Plot of Qualitative Association of BMP (48 horses) vs. N (17 
horses). Horses with any diagnosis compared to normal, healthy horses. 
 
Supplemental Figure 2 Quantile-quantile Plot of Qualitative Association (48 horses) vs. N (17 
horses) 
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Supplemental Figure 3 Manhattan Plot of Qualitative Association of BP (33 horses) vs. MN (32 
horses). Horses with elevated ACTH levels compared to those without elevated ACTH levels. 
 
 
Supplemental Figure 4 Quantile-quantile Plot of Qualitative Association BP (33 horses) vs. MN 
(32 horses). 
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Supplemental Figure 5 Manhattan Plot of Qualitative Association of BM (24 horses) vs. PN (41 
horses). Horses with elevated insulin levels compared to those without elevated insulin levels. 
 
Supplemental Figure 6 Quantile-quantile Plot of Qualitative Association BM (24 horses) vs. PN 
(41 horses). 
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Supplemental Figure 7 Manhattan Plot of Qualitative Association of B (9 horses) vs. PMN (56 
horses). Horses with elevated levels of ACTH and insulin compared to normal, healthy controls 
and those with either ACTH or insulin levels elevated. 
 
Supplemental Figure 8 Quantile-quantile Plot of Qualitative Association B (9 horses) vs. PMN 
(56 horses). 
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Supplemental Figure 9 Manhattan Plot of Qualitative Association of M (15 horses) vs. N (17 
horses). Horses with elevated insulin levels only compared to normal, healthy controls. 
 
 
 
Supplemental Figure 10 Quantile-quantile Plot of Qualitative Association M (15 horses) vs. N 
(17 horses). 
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Supplemental Figure 11 Manhattan Plot of Qualitative Association of BM (24 horses) vs. N (17 
horses). Horses with elevated insulin levels compared to normal, healthy controls. 
 
 
 
Supplemental Figure 12 Quantile-quantile Plot of Qualitative Association BM (24 horses) vs. N 
(17 horses). 
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Supplemental Figure 13 Manhattan Plot of Qualitative Association of M (15 horses vs. BPN (50 
horses). Horses with elevated insulin levels only compared to healthy horses and those with 
elevated ACTH levels. 
 
 
 
Supplemental Figure 14 Quantile-quantile Plot of Qualitative Association M (15 horses vs. BPN 
(50 horses). 
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Supplemental Figure 15 Manhattan Plot of Qualitative Association of BP (33 horses) vs. N (17 
horses). Horses with elevated ACTH levels compared to normal, healthy controls. 
 
 
 
Supplemental Figure 16 Quantile-quantile Plot of Qualitative Association BP (33 horses) vs. N 
(17 horses). 
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Supplemental Figure 17 Manhattan Plot of Qualitative Association of B (9 horses) vs. N (17 
horses). Horses with elevated levels of ACTH and insulin compared to normal, healthy controls.  
 
 
Supplemental Figure 18 Quantile-quantile Plot of Qualitative Association B (9 horses) vs. N (17 
horses). 
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Supplemental Figure 19 Manhattan Plot of Qualitative Association of P (24 horses) vs. N (17 
horses). Horses with elevated ACTH levels only compared to normal, healthy controls. 
 
 
Supplemental Figure 20 Quantile-quantile Plot of Qualitative Association P (24 horses) vs. N (17 
horses). 
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Supplemental Figure 21 Manhattan Plot of Qualitative Association of P (24 horses) vs. BMN (41 
horses). Horses with elevated ACTH levels only compared to normal, healthy controls and those 
with elevated insulin levels. 
 
 
 
Supplemental Figure 22 Quantile-quantile Plot of Qualitative Association P (24 horses) vs. BMN 
(41 horses). 
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Supplemental Figure 23 Manhattan Plot of Qualitative Association of PM (39 horses) vs. N (17 
horses). Horses with either elevated ACTH or insulin levels only compared to normal, healthy 
controls. 
 
 
 
Supplemental Figure 24 Quantile-quantile Plot of Qualitative Association PM (39 horses) vs. N 
(17 horses). 
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Supplemental Figure 25 Manhattan Plot of Qualitative Association of BP (33 horses) vs. M (15 
horses). Horses with elevated ACTH levels compared to those with elevated insulin levels only.  
 
 
 
Supplemental Figure 26 Quantile-quantile Plot of Qualitative Association BP (33 horses) vs. M 
(15 horses). 
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Supplemental Figure 27 Manhattan Plot of Qualitative Association of BM (24 horses) vs. P (24 
horses). Horses with elevated insulin levels compared to those with elevated ACTH levels only. 
 
 
 
Supplemental Figure 28 Quantile-quantile Plot of Qualitative Association BM (24 horses) vs. P 
(24 horses). 
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Supplemental Figure 29 Manhattan Plot of Quantitative Association with Highest Recorded 
Insulin. 
 
 
 
Supplemental Figure 30 Quantile-quantile Plot of Quantitative Association with Highest 
Recorded Insulin. 
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Supplemental Figure 31 Manhattan Plot of Quantitative Association with Highest Recorded 
ACTH. 
 
 
 
Supplemental Figure 32 Quantile-quantile Plot of Quantitative Association with Highest 
Recorded ACTH. 
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Supplemental Figure 33 Manhattan Plot of Qualitative Association with History of Laminitis (26 
cases, 39 controls). 
 
 
Supplemental Figure 34 Quantile-quantile Plot of Quantitative Association with History of 
Laminitis (26 cases, 39 controls). 
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Supplemental Table 1 Table of Significant SNPs from All Associations 
Association N cases/ 
controls 
# Loci/ 
Locus 
info 
Total sig 
SNPs 
Most 
significant 
Best 
P-value 
Nearby 
Genes 
BPMvN 48/17 3 4    
  ECA5 
73.1Mb 
2 BIEC2-
918417 
1.83 e-5 HFM1 
  ECA10 
4.6Mb 
1 BIEC2-95500 1.13 e-5 PEPD 
  ECA21 
1.7Mb 
1 BIEC2-
547188 
2.53 e-5 Eps1511 
CALR3 
CHERP 
BPvMN 33/32 0 0    
BMvPN 24/41 1 1    
  ECA5 
76.2Mb 
1 BIEC2-
919693 
2.1 e-5 No gene 
BvPMN 9/56 10 10    
  ECA5 
22.6Mb 
1 BIEC2-
898132 
7.11 e-6 HMCN1 
AGPAT2 
  ECA5 
22.9Mb 
1 BIEC2-
898144 
1.09 e-5 No gene 
  ECA5 
39.7Mb 
1 BIEC2-
906312 
1.1 e-5 CD1D 
  ECA5 
65.0Mb 
1 BIEC2-
914202 
1.34 e-5 CXorf40B 
  ECA13 
33.3Mb 
1 BIEC2-
232141 
1.75 e-5 CLEC16A 
CG12753 
  ECA14 
87.3Mb 
1 BIEC2-
273090 
1.08 e-5 AP3B1 
  ECA14 
92.1Mb 
1 BIEC2-
276910 
1.47 e-5 No gene 
  ECA15 
78.7Mb 
1 BIEC2-
321447 
1.26 e-5 No gene 
  ECA16 
65.0Mb 
1 BIEC2-
356433 
1.24 e-5 DAZL 
  ECAX 
44.8Mb 
1 BIEC2-
1123081 
1.11 e-5 HUWE1 
MIRLET7F2 
MIR98 
MvN 15v17 1 1    
  ECA27 
28.1Mb 
1 BIEC2-
713528 
1.83 e-5 No gene 
BMvN 24/17 1 1    
  ECA22 
38.8Mb 
1 BIEC2-
596175 
1.6 e-5 BCAS4 
PARD6B 
MvBPN 15/50 0 0 N/A N/A N/A 
BPvN 33/17 2 2    
64 
  ECA9 
58.8Mb 
1 BIEC2-
1097793 
2.26 e-5 SFT2D1 
  ECA10 
4.6Mb 
1 BIEC2-95500 3.63 e-6 PEPD 
BvN 9/17 4 4    
  ECA1 
99.6Mb 
1 BIEC2-42874 2.38 e-5 No gene 
  ECA1 
99.6Mb 
1 BIEC2-42897 2.38 e-5 No gene 
  ECA17 
63.4Mb 
1 BIEC2-
382291 
1.82 e-5 GPC6 
  ECA23 
48.8Mb 
1 BIEC2-
626348 
7.01 e-6 No gene 
PvN 24/17 3 3    
  ECA4 
57.8Mb 
1 BIEC2-
867420 
2.58 e-5 SKAP2 
  ECA9 
58.8Mb 
1 BIEC2-
1097793 
5.11 e-6 SFT2D1 
  ECA10 
4.6Mb 
1 BIEC2-95500 7.07 e-6 PEPD 
PvBMN 24/41 4 4    
  ECA3 
68.9Mb 
1 BIEC2-
789598 
2.03 e-5 No gene 
  ECA4 
57.8Mb 
1 BIEC2-
867420 
2.36 e-5 SKAP2 
  ECA5 
18.9Mb 
1 BIEC2-
897199 
1.69 e-5 CACNA1E 
  ECA5 
39.7Mb 
1 BIEC2-
906312 
1.01 e-5 CD1D 
PMvN 39/17 3 3    
  ECA9 
58.8Mb 
1 BIEC2-
1097793 
1.37 e-5 SFT2D1 
  ECA10 
4.6Mb 
1 BIEC2-95500 2.32 e-5 PEPD 
  ECA16 
40.8Mb 
1 BIEC2-
342954 
2.23 e-5 LZTFL1 
SLC6A20 
CCR9 
BPvM 33/15 0 0 N/A N/A N/A 
BMvP 24/24 2 2    
  ECA5 
18.9Mb 
1 BIEC2-
897199 
1.47 e-5 CACNA1E 
  ECA5 
39.7Mb 
1 BIEC2-
906312 
1.49 e-5 CD1D 
Highest 
Insulin 
N/A 30 38    
65 
  ECA 1 
164.2Mb 
2 BIEC2-78264 6.10 e-6 No gene 
  ECA3 
17.1Mb 
1 BIEC2-
773422 
6.10 e-6 TK2 
CKLF 
CMTM1 
CMTM2 
BEAN1 
  ECA3 
106.8Mb 
2 BIEC2-
808839 
6.10 e-6 LDB1 
LDB2 
  ECA5 
6.1Mb 
1 BIEC2-
890054 
6.10 e-6 SELP 
SELL 
  ECA9 
53.2Mb 
2 BIEC2-
1094996 
6.92 e-6 TMEM74 
  ECA10 
16.4Mb 
1 BIEC2-
104865 
5.18 e-6 PGLYRP1 
CCDC61 
NOVA2 
EBAG9 
  ECA10 
65.9Mb 
1 BIEC2-
130168 
6.10 e-6 DCBLD1 
GOPC 
  ECA11 
44.7Mb 
1 BIEC2-
155077 
7.28 e-6 VPS53 
  ECA11 
48.9Mb 
1 BIEC2-
157582 
6.10 e-6 No gene 
  ECA12 
9.3Mb 
1 BIEC2-
173131 
1.48 e-6 ALX4 
PRRX2 
  ECA13 
37.7Mb 
1 BIEC2-
235337 
6.10 e-6 No gene 
  ECA13 
39.8Mb 
1 BIEC2-
235746 
4.67 e-6 FLYWCH1 
KREMEN2 
PAQR4 
PKMYT1 
CLDN6 
  ECA14 
69.3Mb 
1 BIEC2-
263524 
2.18 e-5 No gene 
  ECA14 
75.6Mb 
1 BIEC2-
266578 
2.15 e-5 No gene 
  ECA15 
14.9Mb 
1 BIEC2-
289514 
3.58 e-6 ANAPC1 
  ECA15 
15.0Mb 
1 BIEC2-
289674 
8.41 e-6 MERTK 
  ECA15 
32.2Mb 
1 BIEC2-
301455 
1.20 e-5 TGFA 
  ECA15 
40.6Mb 
1 BIEC2-
304398 
6.10 e-6 BCL11B 
  ECA16 
4.6Mb 
2 BIEC2-
328336 
6.10 e-6 TMEM40 
RAF1 
66 
  ECA17 
65.2Mb 
1 BIEC2-
382723 
6.10 e-6 ABCC4 
  ECA18 
35.0Mb 
2 BIEC2-
410728 
4.33 e-6 No gene 
  ECA18 
48.1Mb 
1 BIEC2-
412288 
6.10 e-6 No gene 
  ECA18 
55.2Mb 
2 BIEC2-
414366 
6.10 e-6 FUCA1 
  ECA18 
78.7Mb 
2 BIEC2-
421249 
6.10 e-6 No gene 
  ECA18 
81.4Mb 
1 BIEC2-
421894 
7.11 e-6 No gene 
  ECA22 
16.4Mb 
1 BIEC2-
583538 
6.10 e-6 No gene 
  ECA23 
28.6Mb 
1 BIEC2-
622442 
6.10 e-6 PPIB 
  ECA25 
8.2Mb 
1 BIEC2-
657342 
7.15 e-6 ZFP933 
  ECA26 
12.3Mb 
2 BIEC2-
684068 
6.10 e-6 ROBO2 
  ECA29 
26.8Mb 
1 BIEC2-
761473 
2.57 e-5 SFMBT2 
Highest 
ACTH 
N/A 3 3    
  ECA7 
76.9Mb 
1 BIEC2-
1007280 
2.40 e-5 OLFML1 
SYT9 
PPFIBP2 
  ECA13 
20.2Mb 
1 BIEC2-
215377 
4.34 e-7 XPO6 
  ECA17 
50.8Mb 
1 BIEC2-
377685 
3.55 e-6 No gene 
Laminitis 26/39 2 2    
  ECA14 
69.1Mb 
1 BIEC2-
263373 
1.73 e-5 FAM174A 
  ECA14 
69.3Mb 
1 BIEC2-
263524 
2.56 e-6 No gene 
 
 
 
